

Posttraumatic Stress Disorder: Evaluation and Treatment

Zachary Sartor, MD; Lance Kelley, PhD; and Ryan Laschober, MD, Waco Family Medicine Institute, Waco, Texas

Posttraumatic stress disorder (PTSD) is common, with a lifetime prevalence of approximately 6%. PTSD may develop at least one month after a traumatic event involving the threat of death or harm to physical integrity, although earlier symptoms may represent an acute stress disorder. Symptoms typically involve trauma-related intrusive thoughts, avoidant behaviors, negative alterations of cognition or mood, and changes in arousal and reactivity. Assessing for past trauma in patients with anxiety or other psychiatric illnesses may aid in diagnosing and treating PTSD. The *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed., text revision provides diagnostic criteria, and the PTSD Checklist for DSM-5 uses these diagnostic criteria to help physicians diagnose PTSD and determine severity. First-line treatment of PTSD involves psychotherapy, such as trauma-focused cognitive behavior therapy. Pharmacotherapy is useful for patients who have residual symptoms after psychotherapy or are unable or unwilling to access psychotherapy. Selective serotonin reuptake inhibitors (i.e., fluoxetine, paroxetine, and sertraline) and the serotonin-norepinephrine reuptake inhibitor venlafaxine effectively treat primary PTSD symptoms. The addition of other pharmacotherapy, such as atypical antipsychotics or topiramate, may be helpful for residual symptoms. Patients with PTSD often have sleep disturbance related to hyperarousal or nightmares. Prazosin is effective for the treatment of PTSD-related sleep disturbance. Clinicians should consider testing patients with PTSD for obstructive sleep apnea because many patients with PTSD-related sleep disturbance have this condition. Psychiatric comorbidities, particularly mood disorders and substance use, are common in PTSD and are best treated concurrently. (*Am Fam Physician*. 2023; 107(3):273-281. Copyright © 2023 American Academy of Family Physicians.)

Posttraumatic stress disorder (PTSD) is common, occurring in 6% of individuals.¹ It is often undetected in patients presenting to primary care.^{2,3} PTSD can occur in civilian and veteran populations in response to a broad range of traumatic events. PTSD affects people of all ages, and women are twice as likely to receive a diagnosis compared with men.⁴ Symptoms of PTSD typically involve trauma-related intrusive thoughts, avoidant behaviors, negative alterations of cognition or mood, and changes in arousal and reactivity.⁵ Two-thirds of patients with PTSD report moderate to severe symptoms.² PTSD may increase the risk of cardiovascular disease and other medical conditions commonly seen in primary care.⁶

PTSD can be treated in primary care, especially in systems with integrated behavioral health services.⁷ PTSD presents similarly in people with and without military

service, but there are differences. The high prevalence of PTSD shows the importance of diagnosis and treatment by family physicians.

Natural History

PTSD may develop at least one month after a qualifying traumatic event, specifically an event that involves the threat of death or harm to physical integrity. Qualifying traumatic events are common across all ages and socioeconomic groups.⁸ The pathophysiology of PTSD appears to involve impairment in traumatic memory consolidation, leading to maladaptive neuropsychological responses.⁹ Patients often report reexperiencing their trauma, which triggers physiologic and psychological responses that present as primary symptoms of the disorder. Although trauma is common, affecting one-half of adults, less than 10% of patients with traumatic experiences develop PTSD.⁹⁻¹¹ People with more exposure to traumatic events are more likely to develop and have persistent PTSD and report severe PTSD symptoms.¹⁰ This association between cumulative trauma and PTSD partially explains why populations at high risk of recurrent trauma carry a higher PTSD disease burden. For example, patients who identify as LGBTQIA (lesbian, gay, bisexual, transgender, queer [or questioning], intersex, asexual) are

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 226.

Author disclosure: No relevant financial relationships.

Patient information: A handout on this topic, written by the authors of this article, is available with the online version of this article.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Offer trauma-focused psychotherapy to all patients for the treatment of PTSD. ^{25-28,31}	A	Clinical practice guidelines and a network meta-analysis
Consider pharmacologic treatment of PTSD when patients are unable or unwilling to pursue psychotherapy or when patients have residual symptoms after psychotherapy. ²⁷	C	Clinical practice guideline
Because selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors have been found to be the most effective pharmacotherapy for PTSD, consider prescribing fluoxetine, paroxetine, sertraline, and venlafaxine. ^{25-28,33,37}	A	Clinical practice guidelines and systematic reviews
Consider using prazosin for nighttime trauma-related nightmares in patients with PTSD. ^{48,49}	B	Systematic review
Consider screening all patients with PTSD for OSA and treat, if appropriate. ^{50,51}	C	Observational data of high OSA prevalence in patients with PTSD and systematic review of benefits of treating OSA
Although comorbid behavioral health disorders (e.g., depression, substance use) are common in patients with PTSD, do not let the diagnosis of additional disorders preclude treatment of PTSD. ²⁷	C	Clinical practice guideline

OSA = obstructive sleep apnea; PTSD = posttraumatic stress disorder.

A = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

more likely to experience trauma and develop PTSD compared with their peers.¹²

The *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed., text revision (DSM-5-TR) lists the diagnostic criteria for PTSD.⁵ However, patients often report symptoms beyond the core symptoms in the diagnostic criteria. Although presenting symptoms of PTSD often involve psychological symptoms such as hyperarousal, reexperiencing traumatic events, and sleep disturbance, patients often report somatic complaints, such as gastrointestinal distress or musculoskeletal problems.⁹ Psychological symptoms of PTSD can be mistaken for anxiety or mood disorders, which are often comorbid with PTSD. This makes diagnosing PTSD challenging and requires physicians to maintain a low threshold for asking about past trauma for a range of symptoms without other psychological or physiologic explanations.

Screening

Because of the considerable overlap between PTSD and other behavioral health disorders, differentiating PTSD from other disorders can be challenging. Routinely inquiring about past trauma in new patients with undifferentiated

anxiety or mood symptoms may aid in diagnosing and treating PTSD. Despite the high prevalence of PTSD, there are no standardized recommendations for universal adult screening. It is recommended that all veterans be screened for PTSD annually for five years after separation from service, then once every five years thereafter.¹³ A previous *American Family Physician* article on care of the military veteran has more information on screening (<https://www.aafp.org/pubs/afp/issues/2019/1101/p544.html>).

Prevention

Although intervention after trauma is an opportunity to prevent PTSD, there is no consensus on how to prevent PTSD for patients with traumatic exposures. A single session debriefing is not effective at preventing PTSD development.¹⁴ However, early psychological treatments may be helpful. A Cochrane review found low-certainty evidence that multiple early interventions reduced the likelihood of PTSD diagnosis at three to six months after trauma (number needed to treat = 12; 95% CI, 8 to 67), but these interventions may not be effective at one year.¹⁵ Many medications have been proposed to reduce the likelihood of PTSD after

trauma, but most show no evidence of benefit. A 2022 Cochrane review found that hydrocortisone, propranolol, and gabapentin do not prevent PTSD development after a traumatic exposure.¹⁶

Acute Stress Disorder

Acute stress disorder presents with symptoms similar to those of PTSD but occurs exclusively within four weeks of traumatic exposure. It is a risk factor for PTSD; one-half of people diagnosed with acute stress disorder will develop PTSD. However, most individuals with PTSD are not diagnosed with acute stress disorder.¹⁷ Patients with acute stress disorder should receive trauma-focused cognitive behavior therapy because it reduces the risk of long-term symptoms and PTSD.¹⁸ Patients with symptoms of acute

stress disorder lasting longer than one month should be evaluated for PTSD.

Diagnosis of PTSD

Table 1 lists the DSM-5-TR criteria for PTSD.⁵ Trauma exposure is the hallmark criterion of PTSD. Traumas vary, but interpersonal violence, such as sexual assault, physical assault, or military combat, is most likely to lead to PTSD development.¹⁹ Patients do not need to have experienced the trauma directly to meet the criteria. Indirect exposure by witnessing an event or exposure to details of an event can be sufficiently traumatic. Criteria B, C, D, and E organize the symptoms of PTSD. Persistent psychological impairments include hyperarousal, avoidance, intrusive thinking, and negative cognition or mood related to the past traumatic

TABLE 1

Posttraumatic Stress Disorder Diagnostic Criteria in Individuals Older Than 6 Years

A. Exposure to actual or threatened death, serious injury, or sexual violence in one (or more) of the following ways:

1. Directly experiencing the traumatic events.
2. Witnessing, in person, the events as they occurred to others.
3. Learning that the traumatic events occurred to a close family member or close friend. In cases of actual or threatened death of a family member or friend, the events must have been violent or accidental.
4. Experiencing repeated or extreme exposure to aversive details of the traumatic events (e.g., first responders collecting human remains; police officers repeatedly exposed to details of child abuse).

Note: Criterion A4 does not apply to exposure through electronic media, television, movies, or pictures, unless this exposure is work related.

B. Presence of one (or more) of the following intrusion symptoms associated with the traumatic events, beginning after the traumatic events occurred:

1. Recurrent, involuntary, and intrusive distressing memories of the traumatic events.

Note: In children older than 6 years, repetitive play may occur in which themes or aspects of the traumatic events are expressed.

2. Recurrent distressing dreams in which the content and/or affect of the dream is related to the traumatic events.

Note: In children, there may be frightening dreams without recognizable content.

3. Dissociative reactions (e.g., flashbacks) in which the individual feels or acts as if the traumatic events are recurring. (Such reactions may occur on a continuum, with the most extreme expression being a complete loss of awareness of present surroundings.)

Note: In children, trauma-specific reenactment may occur in play.

4. Intense or prolonged psychological distress at exposure to internal or external cues that symbolize or resemble an aspect of the traumatic events.
5. Marked physiological reactions to internal or external cues that symbolize or resemble an aspect of the traumatic events.

C. Persistent avoidance of stimuli associated with the traumatic events, beginning after the traumatic events occurred, as evidenced by one or both of the following:

1. Avoidance of or efforts to avoid distressing memories, thoughts, or feelings about or closely associated with the traumatic events.
2. Avoidance of or efforts to avoid external reminders (people, places, conversations, activities, objects, situations) that arouse distressing memories, thoughts, or feelings about or closely associated with the traumatic events.

continues

TABLE 1 (continued)

Posttraumatic Stress Disorder Diagnostic Criteria in Individuals Older Than 6 Years

D. Negative alterations in cognitions and mood associated with the traumatic events, beginning or worsening after the traumatic event occurred, as evidenced by two (or more) of the following:

1. Inability to remember an important aspect of the traumatic events (typically due to dissociative amnesia and not to other factors such as head injury, alcohol, or drugs).
2. Persistent and exaggerated negative beliefs or expectations about oneself, others, or the world (e.g., "I am bad," "No one can be trusted," "The world is completely dangerous," "My whole nervous system is permanently ruined").
3. Persistent, distorted cognitions about the cause or consequences of the traumatic events that lead the individual to blame themselves or others.
4. Persistent negative emotional state (e.g., fear, horror, anger, guilt, shame).
5. Markedly diminished interest or participation in significant activities.
6. Feelings of detachment or estrangement from others.
7. Persistent inability to experience positive emotions (e.g., inability to experience happiness, satisfaction, or loving feelings).

E. Marked alterations in arousal and reactivity associated with the traumatic events, beginning or worsening after the traumatic events occurred, as evidenced by two (or more) of the following:

1. Irritable behavior and angry outbursts (with little or no provocation) typically expressed as verbal or physical aggression toward people or objects.
2. Reckless or self-destructive behavior.
3. Hypervigilance.
4. Exaggerated startle response.
5. Problems with concentration.
6. Sleep disturbance (e.g., difficulty falling or staying asleep, restless sleep).

F. Duration of the disturbance (Criteria B, C, D, and E) is more than 1 month.

G. The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.

H. The disturbance is not attributable to physiological effects of a substance (e.g., medication, alcohol) or another medical condition.

Specify whether:

With dissociative symptoms: The individual's symptoms meet the criteria for posttraumatic stress disorder, and in addition, in response to the stressor, the individual experiences persistent or recurrent symptoms of either of the following:

1. **Depersonalization:** Persistent or recurrent experiences of feeling detached from, and as if one were an outside observer of, one's mental processes or body (e.g., feeling as though one were in a dream; feeling a sense of unreality of self or body or of time moving slowly).
2. **Derealization:** Persistent or recurrent experiences of unreality of surroundings (e.g., the world around the individual is experienced as unreal, dreamlike, distant, or distorted).

Note: to use this subtype, the dissociative symptoms must not be attributable to the physiological effects of a substance (e.g., blackouts, behavior during alcohol intoxication) or another medical condition (e.g., complex partial seizures).

Specify if:

With delayed expression: If the full diagnostic criteria are not met until at least 6 months after the event (although the onset and expression of some symptoms may be immediate).

Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed., text revision. American Psychiatric Association; 2022:301-303.

experience. Many patients with PTSD have sleep impairment, and symptoms typically present as difficulty falling or staying asleep and sleep disturbances, including nightmares.

Although diagnosis of PTSD is based on the DSM-5-TR criteria, several assessment tools have been created based on these criteria. The diagnostic standard for office-based

assessment of PTSD is the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), a 30-item diagnostic tool based on DSM-5 criteria; it takes up to one hour to administer.²⁰ The 20-item PTSD Checklist for DSM-5 (PCL-5) is a self-reported scale validated against the CAPS-5 that can diagnose PTSD and grade severity.²¹ The PCL-5 is validated for use in civilian and military populations and is available at <https://www.ptsd.va.gov/professional/assessment/adult-sr/ptsd-checklist.asp>.²² Initial and subsequent evaluations should include suicide risk assessment because PTSD is a strong risk factor for suicidal ideation and suicide completion.²³ A diagnostic tool using DSM-5 criteria is also available at <https://www.mdcalc.com/calc/10211/dsm-5-criteria-posttraumatic-stress-disorder>.

Figure 1 outlines the evaluation and management of PTSD.²⁴


Treatment of Psychological Symptoms

PSYCHOTHERAPY

Table 2 presents an overview of PTSD treatment. Psychotherapy is the preferred initial treatment for PTSD and should be offered to all patients.²⁵⁻²⁸ Trauma-focused psychotherapies have high-quality empirical support in the literature and show a superior reduction in PTSD symptoms with a large effect size compared with pharmacotherapy or non-trauma-focused therapies.²⁹⁻³³ Trauma-focused psychotherapy centers around the experience of past traumatic events to aid in psychological processing of the events and changing unhelpful or maladaptive beliefs about past trauma.³⁴ Trauma-focused psychotherapy is a broad category that represents a wide range of manualized therapies, such as cognitive behavior therapy, cognitive therapy, prolonged exposure, and eye movement desensitization and reprocessing. Trauma-focused psychotherapy usually consists of weekly to biweekly sessions lasting 60 to 90 minutes over a period of six to 12 weeks. Most trauma-focused psychotherapy

modalities are proven effective and recommended by the American Psychological Association's clinical practice guideline.²⁶ If patients do not have access to trauma-focused psychotherapy, non-trauma-focused therapies can be effective, although to a lesser extent. Cognitive behavior therapy for PTSD delivered via the internet is effective, although there is less evidence to support its use.³⁵

FIGURE 1



DSM-5 = *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed.; DSM-5-TR = *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed., text revision; PTSD = posttraumatic stress disorder.

Algorithm for the evaluation and management of PTSD.

Adapted with permission from Warner CH, Warner CM, Appenzeller GN, et al. Identifying and managing posttraumatic stress disorder [published correction appears in *Am Fam Physician*. 2014;89(6):424]. *Am Fam Physician*. 2013;88(12):828.

TABLE 2

Treatment of Posttraumatic Stress Disorder

Psychotherapy	Pharmacotherapy	Concurrent treatment
<p>First line: trauma-focused psychotherapy</p> <p>Strongly recommended by the American Psychological Association: prolonged exposure, cognitive processing therapy</p> <p>Conditionally recommended by the American Psychological Association: brief eclectic psychotherapy, narrative exposure therapy, eye movement desensitization and reprocessing</p> <p>If trauma-focused psychotherapy is unavailable: stress inoculation training, present-centered therapy, interpersonal psychotherapy</p>	<p>First line: selective serotonin reuptake inhibitors (i.e., fluoxetine, paroxetine, and sertraline), serotonin-norepinephrine reuptake inhibitor (i.e., venlafaxine)</p> <p>Second line: mirtazapine, tricyclic antidepressants (i.e., imipramine, amitriptyline)</p>	<p>Sleep disturbance: prazosin</p> <p>Obstructive sleep apnea: screen and treat</p> <p>Comorbidities: treat according to specific disorder</p>

INITIAL PHARMACOTHERAPY

Pharmacotherapy is important in the treatment of PTSD. Despite the effectiveness of trauma-focused psychotherapy, up to one-half of patients with PTSD have residual symptoms after treatment.²⁵ Pharmacotherapy is also important for patients who lack access to behavioral health services or prefer pharmacotherapy over psychotherapy. Patients with co-occurring major depressive disorder may be less likely to respond to psychotherapy without pharmacotherapy.³⁶ Therefore, pharmacotherapy is a first-line treatment option for these patients.²⁷

Selective serotonin reuptake inhibitors, including fluoxetine, paroxetine, and sertraline, and the serotonin-norepinephrine reuptake inhibitor venlafaxine are the most effective pharmacologic treatments for PTSD. Paroxetine and fluoxetine are moderately effective in reducing PTSD symptoms.^{25-28,33,37} Paroxetine and venlafaxine are moderately effective in inducing PTSD remission.³³ Sertraline is less effective than paroxetine and venlafaxine for reducing symptoms, and there are no data supporting its use for inducing remission. Despite the benefits of paroxetine, patients are more likely to discontinue this medication due to tolerability issues.³⁷

Alternative medications include mirtazapine and tricyclic antidepressants, specifically amitriptyline and imipramine.^{25,27,37} Because of their significant toxicity profiles, these medications are usually reserved for patients in whom multiple trials of first-line treatments have been ineffective.²⁵

When starting pharmacotherapy, clinicians should discuss medication risks and the probable need for repeated dose increases. By assessing patient response regularly, physicians can titrate medications to the maximum tolerated dose. Patients who do not respond to treatment after eight to 12 weeks of taking a medication at the maximum tolerated dose should switch to another medication.²⁵

ADDITIONAL PHARMACOTHERAPY

Other medications may be helpful as alternate or supplemental therapy for patients who experience only partial benefit from pharmacotherapy. The atypical antipsychotics risperidone (Risperdal) and olanzapine (Zyprexa) slightly improve PTSD-related symptoms.³³ Risperidone has the most evidence, mainly in the military population.^{38,39} Patients taking risperidone may have extrapyramidal symptoms or movement disorder-related toxicity, and both risperidone and olanzapine could cause significant metabolic-related toxicity.⁴⁰ Aripiprazole appears to be effective for PTSD treatment and has fewer metabolic risks.⁴⁰⁻⁴²

Topiramate might be helpful for PTSD symptoms, although the benefit may be small.³³ According to one small trial, topiramate may be effective at reducing alcohol use and PTSD symptoms in veterans with comorbid alcohol use disorder and PTSD.⁴³

Treatment of Sleep Disturbance

PSYCHOTHERAPY

Patients with PTSD may have issues with sleep initiation or maintenance. With similar effectiveness in patients with PTSD as those without PTSD, cognitive behavior therapy for insomnia is recommended as a first-line treatment for patients with PTSD and chronic sleep disturbance.^{27,44-46}

PHARMACOTHERAPY

Sedative hypnotic agents, such as benzodiazepines, the nonbenzodiazepine z-drugs (i.e., eszopiclone [Lunesta], zaleplon, and zolpidem), and trazodone may help patients with sleep disturbance. The misuse potential and chronic long-term effects of benzodiazepines make them less desirable. Patients with PTSD who are taking sedative hypnotic agents are less likely to respond to cognitive behavior therapy for insomnia.⁴⁷ PTSD-related sleep impairment is often

chronic, increasing the risk of long-term sedative hypnotics use. Cognitive behavior therapy for insomnia is recommended before prescribing these medications.²⁷

If patients experience mid-sleep awakening due to hyperarousal or nightmares, the α_1 antagonist prazosin may reduce symptoms by decreasing sympathetic nervous tone during sleep. [corrected] A recent randomized controlled trial showed that prazosin did not reduce nightmare occurrence or improve sleep quality compared with placebo, but a systematic review that included this trial demonstrated that prazosin reduced nightmares without improving overall symptoms or sleep quality.^{48,49}

OBSTRUCTIVE SLEEP APNEA

Obstructive sleep apnea is common in patients with PTSD. Three-fourths of patients with PTSD have sleep apnea on polysomnography, and nearly one-half have at least moderate obstructive sleep apnea.⁵⁰ Continuous positive airway pressure reduces nightmares and improves daytime symptoms in patients with PTSD and obstructive sleep apnea.⁵¹ Adherence to continuous positive airway pressure is lower when patients have PTSD, increasing the importance of monitoring. Physicians should consider asking about barriers to continuous positive airway pressure adherence and offer counseling.⁵⁰ Oral mandibular repositioning devices are effective for patients with mild to moderate obstructive sleep apnea. In a study of veterans with PTSD, oral devices were nearly as effective as continuous positive airway pressure and were used for an average of two hours more each night.⁵² Patients unable to adhere to continuous positive airway pressure may benefit from these oral devices as alternative therapies.

Behavioral Health Comorbidities

Most patients with PTSD have comorbidities. Physicians should evaluate for and treat behavioral health comorbidities concurrently when diagnosing patients with PTSD. Diagnosis of additional disorders should not preclude treatment of PTSD.²⁷ Depression co-occurs in up to one-half of all patients with PTSD and is more common in veterans and survivors of interpersonal violence.⁵³ Patients with PTSD and depression are more likely to require pharmacotherapy to improve symptoms.³⁶

Substance use disorders are common in patients with PTSD and 40% of patients with PTSD meet criteria for alcohol use disorder.⁵⁴ Patients with PTSD and substance use report more functional impairment and have twice the suicide risk of patients with PTSD alone.^{55,56} PTSD and substance use disorder should be treated concurrently.⁵⁷ Trauma-focused psychotherapy may be less effective when PTSD is complicated by substance use.⁵⁸ However, a recent study shows that

cognitive processing therapy reduces PTSD symptoms and drinking in patients with alcohol use disorder.⁵⁹

This article updates a previous article on this topic by Warner, et al.²⁴

Data Sources: A PubMed search was completed using the key terms PTSD, trauma-related disorders, treatment, psychological treatment, pharmacotherapy, and comorbidities. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. The Agency for Healthcare Research and Quality Effective Healthcare Reports and the Cochrane database were also searched. We reviewed guidelines from the American Psychological Association, American Psychiatric Association, National Institute for Health and Care Excellence, and the U.S. Department of Veterans Affairs. Studies that used race and/or gender as patient categories but did not define how these categories were assigned were not included in our final review. Search dates: March 28, 2022 and December 16, 2022.

The Authors

ZACHARY SARTOR, MD, is a faculty member at Waco (Tex.) Family Medicine Institute.

LANCE KELLEY, PhD, is a faculty member at Waco Family Medicine Institute and deputy chief behavioral health officer at Waco (Tex.) Family Medicine.

RYAN LASCHOB, MD, is a faculty member and residency program director at Waco Family Medicine Institute.

Address correspondence to Zachary Sartor, MD, 1600 Providence Dr., Waco, TX 76707 (email: zach.sartor@wacofamilymedicine.org). Reprints are not available from the authors.

References

1. Gradus JL. Epidemiology of PTSD. National Center for PTSD; U.S. Department of Veterans Affairs. October 6, 2022. Accessed December 16, 2022. <https://www.ptsd.va.gov/professional/treat/essentials/epidemiology.asp>
2. National Institute of Mental Health. Post-Traumatic Stress Disorder. Accessed February 12, 2022. <https://www.nimh.nih.gov/health/topics/post-traumatic-stress-disorder-ptsd>
3. Spoont MR, Williams JW Jr, Kehle-Forbes S, et al. Does this patient have posttraumatic stress disorder?: Rational clinical examination systematic review [published correction appears in JAMA. 2016;315(1):90]. *JAMA*. 2015;314(5):501-510.
4. Harvard Medical School. *National Comorbidity Survey (NCS)*. 2017. Accessed February 12, 2022. <https://www.hcp.med.harvard.edu/ncs/index.php>
5. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed., text revision. American Psychiatric Association; 2022.
6. Ryder AL, Azcarate PM, Cohen BE. PTSD and physical health. *Curr Psychiatry Rep*. 2018;20(12):116.
7. Bohnert KM, Sripada RK, Mach J, et al. Same-day integrated mental health care and PTSD diagnosis and treatment among VHA primary care patients with positive PTSD screens. *Psychiatr Serv*. 2016;67(1):94-100.
8. Kilpatrick DG, Resnick HS, Milanak ME, et al. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. *J Trauma Stress*. 2013;26(5):537-547.

9. Yehuda R, Hoge CW, McFarlane AC, et al. Post-traumatic stress disorder. *Nat Rev Dis Primers*. 2015;1:15057.
10. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry*. 1995;52(12):1048-1060.
11. National Center for PTSD. How common is PTSD in adults? U.S. Department of Veterans Affairs. August 29, 2022. Accessed July 18, 2022. https://www.ptsd.va.gov/understand/common/common_adults.asp
12. Livingston NA, Berke D, Scholl J, et al. Addressing diversity in PTSD treatment: clinical considerations and guidance for the treatment of PTSD in LGBTQ populations. *Curr Treat Options Psychiatry*. 2020;7(2):53-69.
13. Yedlinsky NT, Neff LA, Jordan KM. Care of the military veteran: selected health issues. *Am Fam Physician*. 2019;100(9):544-551.
14. Rose S, Bisson J, Churchill R, et al. Psychological debriefing for preventing post traumatic stress disorder (PTSD). *Cochrane Database Syst Rev*. 2002;(2):CD000560.
15. Roberts NP, Kitchiner NJ, Kenardy J, et al. Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. *Cochrane Database Syst Rev*. 2019;(8):CD006869.
16. Bertolini F, Robertson L, Bisson JI, et al. Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD). *Cochrane Database Syst Rev*. 2022;(2):CD013443.
17. Bryant RA. Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review. *J Clin Psychiatry*. 2011;72(2):233-239.
18. Kliem S, Kröger C. Prevention of chronic PTSD with early cognitive behavioral therapy. A meta-analysis using mixed-effects modeling. *Behav Res Ther*. 2013;51(11):753-761.
19. Jakob JMD, Lamp K, Rauch SAM, et al. The impact of trauma type or number of traumatic events on PTSD diagnosis and symptom severity in treatment seeking veterans. *J Nerv Ment Dis*. 2017;205(2):83-86.
20. National Center for PTSD. Clinician-administered PTSD scale for DSM-5 (CAPS-5). U.S. Department of Veterans Affairs. October 21, 2022. Accessed July 6, 2022. <https://www.ptsd.va.gov/professional/assessment/adult-int/caps.asp>
21. Weathers FW, Litz BT, Keane TM, et al. PTSD checklist for DSM-5 (PCL-5). April 11, 2018. Accessed February 12, 2022. https://www.ptsd.va.gov/professional/assessment/documents/PCL5_Standard_form.PDF
22. LeardMann CA, McMaster HS, Warner S, et al. Comparison of posttraumatic stress disorder checklist instruments from *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition vs Fifth Edition in a large cohort of US military service members and veterans. *JAMA Netw Open*. 2021;4(4):e218072.
23. Sareen J, Cox BJ, Stein MB, et al. Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample. *Psychosom Med*. 2007;69(3):242-248.
24. Warner CH, Warner CM, Appenzeller GN, et al. Identifying and managing posttraumatic stress disorder [published correction appears in *Am Fam Physician*. 2014;89(6):424]. *Am Fam Physician*. 2013;88(12):827-834.
25. Katzman MA, Bleau P, Blier P, et al.; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/ Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. *BMC Psychiatry*. 2014;14(suppl 1):S1.
26. Guideline Development Panel for the Treatment of PTSD in Adults. Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. American Psychological Association; 2017. Accessed February 12, 2022. <https://www.apa.org/ptsd-guideline/ptsd.pdf>
27. The Management of Posttraumatic Stress Disorder Work Group. VA/ DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. U.S. Department of Veterans Affairs/Department of Defense; 2017. Accessed February 12, 2022. <https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf>
28. National Institute for Health and Care Excellence. Post-traumatic stress disorder. NICE guideline [NG116]. December 5, 2018. Accessed February 12, 2022. <https://www.nice.org.uk/guidance/ng116>
29. Bisson JI, Roberts NP, Andrew M, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. *Cochrane Database Syst Rev*. 2013;(12):CD003388.
30. Lee DJ, Schnitzlein CW, Wolf JP, et al. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. *Depress Anxiety*. 2016;33(9):792-806.
31. Merz J, Schwarzer G, Gerger H. Comparative efficacy and acceptability of pharmacological, psychotherapeutic, and combination treatments in adults with posttraumatic stress disorder: a network meta-analysis. *JAMA Psychiatry*. 2019;76(9):904-913.
32. Coventry PA, Meader N, Melton H, et al. Psychological and pharmacological interventions for adults with posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: systematic review and component network meta-analysis. *PLoS Med*. 2020;17(8):e1003262.
33. Forman-Hoffman V, Middleton JC, Feltner C, et al. Psychological and pharmacological treatments for adults with posttraumatic stress disorder: a systematic review update. Agency for Healthcare Research and Quality; 2018. Accessed February 12, 2022. <https://effectivehealthcare.ahrq.gov/products/ptsd-adult-treatment-update/research-2018>
34. National Center for PTSD. PTSD Treatment Basics. U.S. Department of Veterans Affairs. August 10, 2022. Accessed July 5, 2022. www.ptsd.va.gov/understand_tx/tx_basics.asp
35. Simon N, Robertson L, Lewis C, et al. Internet-based cognitive and behavioural therapies for post-traumatic stress disorder (PTSD) in adults. *Cochrane Database Syst Rev*. 2021;(5):CD011710.
36. Stewart CL, Wrobel TA. Evaluation of the efficacy of pharmacotherapy and psychotherapy in treatment of combat-related post-traumatic stress disorder: a meta-analytic review of outcome studies. *Mil Med*. 2009;174(5):460-469.
37. Williams T, Phillips NJ, Stein DJ, et al. Pharmacotherapy for post traumatic stress disorder (PTSD). *Cochrane Database Syst Rev*. 2022;(3):CD002795.
38. Rothbaum BO, Killeen TK, Davidson JRT, et al. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. *J Clin Psychiatry*. 2008;69(4):520-525.
39. Krystal JH, Rosenheck RA, Cramer JA, et al.; Veterans Affairs Cooperative Study No. 504 Group. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. *JAMA*. 2011;306(5):493-502.
40. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis [published correction appears in *Lancet*. 2019;394(10202):918]. *Lancet*. 2019;394(10202):939-951.
41. Robert S, Hamner MB, Durkalski VL, et al. An open-label assessment of aripiprazole in the treatment of PTSD. *Psychopharmacol Bull*. 2009;42(1):69-80.
42. Richardson JD, Fikretoglu D, Liu A, et al. Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review. *BMC Psychiatry*. 2011;11:86.
43. Batki SL, Pennington DL, Lasher B, et al. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. *Alcohol Clin Exp Res*. 2014;38(8):2169-2177.

POSTTRAUMATIC STRESS DISORDER

44. Qaseem A, Kansagara D, Forciea MA. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 2016;165(2):125-133.
45. Miller KE, Brownlow JA, Gehrman PR. Sleep in PTSD: treatment approaches and outcomes. *Curr Opin Psychol.* 2020;34:12-17.
46. Carlson GC, Kelly MR, Mitchell M, et al. Benefits of cognitive behavioral therapy for insomnia for women veterans with and without probable post-traumatic stress disorder. *Womens Health Issues.* 2022;32(2):194-202.
47. El-Solh AA, O'Brien N, Akinnusi M, et al. Predictors of cognitive behavioral therapy outcomes for insomnia in veterans with post-traumatic stress disorder. *Sleep Breath.* 2019;23(2):635-643.
48. Raskind MA, Peskind ER, Chow B, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. *N Engl J Med.* 2018;378(6):507-517.
49. Zhang Y, Ren R, Sanford LD, et al. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. *Sleep Med.* 2020;67:225-231.
50. Zhang Y, Weed JG, Ren R, et al. Prevalence of obstructive sleep apnea in patients with posttraumatic stress disorder and its impact on adherence to continuous positive airway pressure therapy: a meta-analysis. *Sleep Med.* 2017;36:125-132.
51. Zhang Y, Ren R, Yang L, et al. The effect of treating obstructive sleep apnea with continuous positive airway pressure on posttraumatic stress disorder: a systematic review and meta-analysis with hypothetical model. *Neurosci Biobehav Rev.* 2019;102:172-183.
52. El-Solh AA, Homish GG, Ditursi G, et al. A randomized crossover trial evaluating continuous positive airway pressure versus mandibular advancement device on health outcomes in veterans with posttraumatic stress disorder. *J Clin Sleep Med.* 2017;13(11):1327-1335.
53. Rytwinski NK, Scur MD, Feeny NC, et al. The co-occurrence of major depressive disorder among individuals with posttraumatic stress disorder: a meta-analysis. *J Trauma Stress.* 2013;26(3):299-309.
54. Pietrzak RH, Goldstein RB, Southwick SM, et al. Prevalence and axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *J Anxiety Disord.* 2011;25(3):456-465.
55. Simpson TL, Rise P, Browne KC, et al. Clinical presentations, social functioning, and treatment receipt among individuals with comorbid lifetime PTSD and alcohol use disorders versus drug use disorders: findings from NESARC-III. *Addiction.* 2019;114(6):983-993.
56. Leeies M, Pagura J, Sareen J, et al. The use of alcohol and drugs to self-medicate symptoms of posttraumatic stress disorder. *Depress Anxiety.* 2010;27(8):731-736.
57. National Center for PTSD. Treatment of co-occurring PTSD and substance use disorder in VA. U.S. Department of Veterans Affairs. October 6, 2022. Accessed July 7, 2022. https://www.ptsd.va.gov/professional/treat/cooccurring/tx_sud_va.asp
58. Roberts NP, Roberts PA, Jones N, et al. Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder. *Cochrane Database Syst Rev.* 2016;(4):CD010204.
59. Simpson TL, Kaysen DL, Fleming CB, et al. Cognitive processing therapy for relapse prevention for comorbid posttraumatic stress disorder and alcohol use disorder: a randomized clinical trial. *Plos One.* 2022;17(11):e0276111.